Here are several reasons Pfizer needs to sharpen its pencil

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Bolstering its claim that Pfizer's (PFE) offer undervalues its pipeline, AstraZeneca (AZN) releases promising data on its lung cancer drug AZD9291. In a 199-cohort Phase 1 clinical trial, it shrank tumors in 51% of patients and 64% of patients with the T790M genetic mutation, which develops in ~50% of non-small cell lung cancer cases that become resistant to EGFR inhibitors.

A Phase 2 trial is underway in patients with the T790M mutation at a daily dose of 80 mg. If all goes well, AZN will submit its regulatory filing as early as 2H 2015.

The company believes that AZD9291 could achieve peak sales of $3B.

Another promising product is MEDI4736, a cancer immunotherapy known as an anti-PDL-1, currently being tested for non-small lung cancer. The firm believes it could achieve peak sales of $6.5B.

Yet another is olaparib, a PARP inhibitor being tested for ovarian cancer. Management believes peak sales could hit $2B.